Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epanova in severe hypertriglyceridemia
2010-024064-18Phase 3Completed
- Sponsor
- Omthera Pharmaceuticals
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eicosapentaenoic acid + docosahexaenoic acid in hypertriglyceridemia (4 arms), sponsored by Omthera Pharmaceuticals. Primary endpoints: Percent change in triglycerides from baseline to end of treatment and Safety and tolerability by adverse events. Started Feb 2011; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on 2010-024064-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024064-18.